John E Harris, Dermatology Meeting News 2021: Efficacy and Safety of Ruxolitinib in Vitiligo
We caught up with Prof. John E Harris (University of Massachusetts Medical School, MA, USA) to discuss the safety and efficacy results from a Phase 2 study (NCT03099304) investigating ruxolitinib cream, a JAK1/ JAK2 inhibitor, in adults with vitiligo.
His abstract entitled ‘Safety and Efficacy of Ruxolitinib Cream for the Treatment of Vitiligo: 104-Week Data From a Phase 2 Study‘ was presented at the AAD VMX, 23-25 April 2021.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.
- What is the rationale for the use of ruxolitinib cream in the treatment of adults with vitiligo? (0:05)
- What was the design of the Phase 2 study, and what did the primary data analysis teach us? (1:19)
- How did the 104-week data compare to that at 52 weeks in terms of the efficacy endpoints? (2:02)
- What was the safety profile of treatment with ruxolitinib cream over 104 weeks? (2:40)
- What is the clinical significance of these findings? (3:32)
Disclosures: Prof. John E Harris has acted and a consultant and investigator for Pfizer, Genzyme/ Sanofi, Incyte, Rheos Medicines, Sun Pharmaceutical, LEO Pharma, Villaris Therapeutics, Dermavant and TeVido BioDevices; a consultant for AbbVie, Janssen, Almirall, Methuselah Health, Pandion, AnaptysBio, Avita, NIRA Biosciences, Admirx, Granular Therapeutics and Platelet BioGenesis; has Equity in TeVido Biodevices, Rheos, Villaris Therapeutics, NIRA Biosciences and is Founder of Villaris Therapeutics and NIRA Biosciences.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Vitiligo
Amit G. Pandya, Dermatology Meeting News 2023: Efficacy & safety of ruxolitinib cream in vitiligo – findings from the TRuE-V phase 3 studies
TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) were randomized, double-blind, vehicle-controlled phase 3 studies that investigated ruxolinitib cream for the treatment of vitiligo over 52 weeks. We were delighted to speak to Dr. Amit G. Pandya (Palo Alto Foundation Medical Group, Sunnyvale, CA, USA) around the efficacy and safety findings from the TRuE-V phase 3 studies and […]
Amit G. Pandya, Dermatology Meeting News 2023: JAK inhibitors for the treatment of vitiligo
Ruxolitinib cream, a cream formulation of the JAK 1/JAK2 inhibitor was first approved for use in vitiligo by the FDA in July 2022 and is the only topical treatment approved for repigmentation. We were delighted to speak to Dr. Amit G. Pandya (Palo Alto Foundation Medical Group, Sunnyvale, CA, USA) around the rationale and adverse […]
Thierry Passeron, EADV 2022: Efficacy of Ruxolitinib Cream by Body Region in Vitiligo – A Pooled Analysis of the TRuE-V Phase 3 Studies
TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) were randomized, double-blind, vehicle-controlled phase 3 studies investigating ruxolitinib cream in adults and adolescents with vitiligo. touchIMMUNOLOGY were delighted to speak with Prof. Thierry Passeron (University Hospital of Nice, Nice, France) to discuss the rationale and findings from his pooled analysis looking at the effect of ruxolitinib cream on achievement […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!